Aim The role of Sirtuin 1 (SIRT 1) in carcinogenesis is controversial. This study was to explore the association between the SIRT1 expression and the clinical characteristics, the responsiveness to chemotherapy and prognosis in Non-small cell lung cancer (NSCLC). Methods We enrolled 295 patients with inoperable advanced stage of NSCLC, namely, stage III (A+B) and IV NSCLC. All patients had received platinum-based chemotherapy after diagnosis and the chemotherapy response were evaluated. All patients were followed up for overall survival (OS) and progression free survival (PFS). In vitro, H292 cells were tranfected with SIRT1 small interfering RNA (siRNA). The cell biological behaviors and chemosensitivity to cisplatin treatment were studied. The in vivo tumorgenesis and metastasis assays were performed in nude mice. Results We found that the SIRT1 expressions were significantly associated with the tumor stage, tumor size and differentiation status. Patients with high SIRT 1 expressions had a significantly higher chance to be resistant to chemotherapy than those with low SIRT 1 expression. Patients with high expression of SIRT1 had significantly shorter OS and DFS than those with low expression. Cox analyses confirmed that the SIRT 1 expression was a strong predictor for a poor OS and PFS in NSCLC patients underwent Platinum-based chemotherapy. In vitro studies revealed that the reduced expression SIRT 1 by siRNA technique significantly inhibited cell proliferation, migration and invasion. More importantly, SIRT1 si-RNA significantly enhanced the chemosensitivity of H292 cells to cisplatin treatment. The in vivo tumorgenesis and metastasis assays showed that SIRT1 knockdown dramatically reduced the tumor volume and the metastatic ability in nude mice. Conclusion Collectively, our data suggest that the SIRT1 expression may be a molecular marker associated with the NSLCLC clinical features, treatment responsiveness and prognosis of advanced NSCLC.
References
[1]
Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S et al. (2013) Lung cancer biomarkers: State of the art. J Carcinog 12: 3. doi:10.4103/1477-3163.107958. PubMed: 23599685.
[2]
Tsim S, O'Dowd CA, Milroy R, Davidson S (2010) Staging of non-small cell lung cancer (NSCLC): a review. Respir Med 104: 1767-1774. doi:10.1016/j.rmed.2010.08.005. PubMed: 20833010.
[3]
Kosmidis P (2002) Chemotherapy in NSCLC: historical review. Lung Cancer 38 Suppl 3: S19-S22. doi:10.1016/S0169-5002(02)00261-1. PubMed: 12468139.
[4]
Hildebrandt MA, Gu J, Wu X (2009) Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 5: 745-755. doi:10.1517/17425250902973711. PubMed: 19442035.
[5]
Gridelli C, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D et al. (2002) Chemotherapy of advanced NSCLC in the elderly. Tumori 88: S143-S144. PubMed: 11989910.
[6]
Stuschke M, P？ttgen C (2010) Chemotherapy: Effectiveness of adjuvant chemotherapy for resected NSCLC. Nat Rev Clin Oncol 7: 613-614. doi:10.1038/nrclinonc.2010.165. PubMed: 20981122.
[7]
Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD (2008) Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer 122: 1810-1819. PubMed: 18074354.
[8]
Sauve AA, Wolberger C, Schramm VL, Boeke JD (2006) The biochemistry of sirtuins. Annu Rev Biochem 75: 435-465. doi:10.1146/annurev.biochem.74.082803.133500. PubMed: 16756498.
[9]
Fusco S, Maulucci G, Pani G (2012) Sirt1: def-eating senescence? Cell Cycle 11: 4135-4146. doi:10.4161/cc.22074. PubMed: 22983125.
[10]
Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI et al. (2012) SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLOS ONE 7: e45119. doi:10.1371/journal.pone.0045119. PubMed: 23024800.
[11]
Chen W, Bhatia R (2013) Roles of SIRT1 in leukemogenesis. Curr Opin Hematol, 20: 308–13. PubMed: 23519155.
[12]
Li X (2013) SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai) 45: 51-60. doi:10.1093/abbs/gms108.
[13]
Lee H, Kim KR, Noh SJ, Park HS, Kwon KS et al. (2011) Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 42: 204-213. doi:10.1016/j.humpath.2010.05.023. PubMed: 21056897.
[14]
Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA et al. (2007) SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618. doi:10.1158/0008-5472.CAN-07-0085. PubMed: 17638871.
[15]
Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T et al. (2012) SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep 27: 1726-1732. PubMed: 22470132.
[16]
Bae HJ, Chang YG, Noh JH, Kim JK, Eun JW et al. (2012) DBC1 does not function as a negative regulator of SIRT1 in liver cancer. Oncol Lett 4: 873-877. PubMed: 23162614.
[17]
Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K et al. (2006) Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25: 176-185. PubMed: 16170353.
[18]
Sun Y, Sun D, Li F, Tian L, Li C et al. (2007) Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 58: 21-29. doi:10.1016/j.lungcan.2007.05.013. PubMed: 17624472.
[19]
Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL (2012) SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 19: 2011-2019. doi:10.1245/s10434-011-2159-4. PubMed: 22146883.
[20]
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA et al. (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714. doi:10.1097/JTO.0b013e31812f3c1a. PubMed: 17762336.
[21]
Wu F, Hu N, Li Y, Bian B, Xu G et al. (2012) Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cell Oncol (Dordr) 35: 175-180.
[22]
Remmele W, Stegner HE (1987) [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8: 138-140. PubMed: 3303008.
[23]
Zhou C, Liu G, Wang L, Lu Y, Yuan L et al. (2013) MiR-339-5p Regulates the Growth, Colony Formation and Metastasis of Colorectal Cancer Cells by Targeting PRL-1. PLOS ONE 8: e63142. doi:10.1371/journal.pone.0063142. PubMed: 23696794.
[24]
Dai C, Zhang B, Liu X, Ma S, Yang Y et al. (2013) Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 154: 1247-1259. doi:10.1210/en.2012-1908. PubMed: 23384836.
[25]
Sundaresan NR, Pillai VB, Gupta MP (2011) Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol 51: 614-618. doi:10.1016/j.yjmcc.2011.01.008. PubMed: 21276800.
[26]
Kong S, McBurney MW, Fang D (2012) Sirtuin 1 in immune regulation and autoimmunity. Immunol Cell Biol 90: 6-13. doi:10.1038/icb.2011.102. PubMed: 22105513.
[27]
Metoyer CF, Pruitt K (2008) The role of sirtuin proteins in obesity. Pathophysiology 15: 103-108. doi:10.1016/j.pathophys.2008.04.002. PubMed: 18599274.
Zschoernig B, Mahlknecht U (2008) SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun 376: 251-255. doi:10.1016/j.bbrc.2008.08.137. PubMed: 18774777.
[30]
Oppenheimer H, Gabay O, Meir H, Haze A, Kandel L et al. (2012) 75-kd sirtuin 1 blocks tumor necrosis factor alpha-mediated apoptosis in human osteoarthritic chondrocytes. Arthritis Rheum 64: 718-728. doi:10.1002/art.33407. PubMed: 21987377.
[31]
Kozako T, Aikawa A, Shoji T, Fujimoto T, Yoshimitsu M et al. (2012) High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. Int J Cancer 131: 2044-2055. doi:10.1002/ijc.27481. PubMed: 22322739.
[32]
Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S et al. (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLOS ONE 3: e2020. doi:10.1371/journal.pone.0002020. PubMed: 18414679.
[33]
Wu M, Wei W, Xiao X, Guo J, Xie X et al. (2012) Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol 29: 3240-3249. doi:10.1007/s12032-012-0260-6. PubMed: 22661383.
[34]
Wang RH, Sengupta K, Li C, Kim HS, Cao L et al. (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323. doi:10.1016/j.ccr.2008.09.001. PubMed: 18835033.
[35]
Fu M, Liu M, Sauve AA, Jiao X, Zhang X et al. (2006) Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 26: 8122-8135. doi:10.1128/MCB.00289-06. PubMed: 16923962.
[36]
Xie Y, Zhang J, Xu Y, Shao C (2012) SirT1 confers hypoxia-induced radioresistance via the modulation of c-Myc stabilization on hepatoma cells. J Radiat Res 53: 44-50. doi:10.1269/jrr.11062. PubMed: 22302044.
[37]
Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C et al. (2009) Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 380: 236-242. doi:10.1016/j.bbrc.2009.01.040. PubMed: 19166820.
[38]
Matsushita N, Takami Y, Kimura M, Tachiiri S, Ishiai M et al. (2005) Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 10: 321-332. doi:10.1111/j.1365-2443.2005.00836.x. PubMed: 15773895.
[39]
Brooks CL, Gu W (2009) Anti-aging protein SIRT1: a role in cervical cancer? Aging (Albany NY) 1: 278-280. PubMed: 20157516.
[40]
Brooks CL, Gu W (2009) How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 9: 123-128. doi:10.1038/nrc2562. PubMed: 19132007.
[41]
Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV et al. (2013) SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate 73: 522-530. doi:10.1002/pros.22592. PubMed: 23038275.
